Bridgewater cancer firm announces new CMO

By Carmen Triola
Bridgewater | Jan 18, 2018 at 12:37 pm

Clinical Genomics, which specializes in cancer diagnostic solutions and liquid biopsy tests, has appointed Dr. Tadd Lazarus as chief medical officer.

“I am very excited to be a part of Clinical Genomics — the leader in both the screening and monitoring of colorectal cancer,” Lazarus said. “The combination of our innovative products will continue to be instrumental in reducing both the morbidity and mortality of this disease.”

Lazarus has spent over 20 years in the biotechnology industry. Before Bridgewater-based Clinical Genomics, he served as senior vice president and CMO for Luminex. He also worked as CMO and head of medical & scientific affairs, reimbursement and public policy at Qiagen. He also headed a clinical trial research team as CMO and VP of clinical affairs at Gen-Probe Inc., now known as Hologic.

“We are extremely pleased to welcome Dr. Lazarus to the Clinical Genomics team, and are looking forward to gaining the benefit of his clinical expertise and passionate patient advocacy as we strive towards our company goals,” said Lawrence LaPointe, CEO of Clinical Genomics.